Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma.


Journal

Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761

Informations de publication

Date de publication:
20 May 2020
Historique:
received: 29 01 2020
revised: 19 02 2020
accepted: 20 02 2020
pubmed: 26 2 2020
medline: 14 4 2020
entrez: 26 2 2020
Statut: ppublish

Résumé

Clear cell renal cell carcinoma (ccRCC) is one of the deadly diseases with poor metastatic disease prognosis. There is an urgent need to explore the potential molecular markers which can improve the prognosis of the disease. Histone demethylases have emerged as a powerful tool for cancer prognosis and therapeutics during the last decade. The implications of demethylases of histone 3 lysine 4 (H3K4) in ccRCC are however unrevealed. We therefore evaluated the expression of H3K4 demethylases in ccRCC, with emphasis on their clinical significance as a prognostic marker. Total 50 histopathological confirmed cases of ccRCC were enrolled in the study. The expression of seven H3K4 demethylases was determined by Real-Time PCR using gene specific primers and correlated with tumor stage, grade and metastasis. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the prognostic significance of H3K4 demethylases. The median age of the patients was 54 years with predominance of male patients by 2.6-fold. Among seven genes viz FBXL10, LSD1, LSD2, KDM5A, KDM5B, KDM5C and KDM5D analyzed, LSD2 was found to be significantly associated with tumor stage and metastasis. The optimal cut-off value for LSD2 was 3.2 as calculated from ROC curve analysis for metastasis as well as TNM stage with area under curve of 0.74 and 0.78 respectively. In addition, LSD2 expression showed significant positive correlation with LSD1 expression in tumor metastasis. The expression of LSD2 was associated with higher TNM stage and metastasis of the tumor and thus, might serve as a useful marker for ccRCC progression.

Identifiants

pubmed: 32097694
pii: S0378-1119(20)30167-0
doi: 10.1016/j.gene.2020.144498
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Histone Demethylases EC 1.14.11.-
KDM1B protein, human EC 1.14.11.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

144498

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Aman Kumar (A)

Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Niti Kumari (N)

Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Nayudu Nallabelli (N)

Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Ujjawal Sharma (U)

Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Ashutosh Rai (A)

Department of Translational and Regenerative Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Shrawan Kumar Singh (SK)

Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Nandita Kakkar (N)

Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Rajendra Prasad (R)

Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Department of Biochemistry, MM Institute of Medical Science and Research, MM (Deemed to be University), Mullana, Ambala, Haryana, India. Electronic address: fateh1977@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH